"iPSC-derived human cells are a very promising approach to drug discovery and toxicology testing and have many advantages over current cell models," said Chris Parker, chief commercial officer of CDI and co-chairperson of the workshop.  "We organized this workshop, in collaboration with one of our customers, Roche, to present the iPSC-based cell model to the pharmaceutical toxicology community."

The presentation schedule:

Human Inducible Pluripotent Stem Cell Derived In Vitro Models “ the Path to a Better Understanding of Individual Biology and Their Utility in Drug Discovery and Development, Chris Parker, CDI, Madison, WIApplication of Stem Cell-Derived Cardiomyocytes in Toxicology and Safety Pharmacology, Kyle Kolaja, Roche, Nutley, NJPharmaceutical Perspectives on Introduction of Regenerative Medicine Concepts into the Existing Pharmaceutical Paradigm, Ruth McKernan, Pfizer, Groton, CTDeveloping Stem Cell-Based Therapies: FDA Product and Preclinical Regulatory Considerations, Mercedes Serabian, U.S. FDA, Silver Spring, MDHow the Understanding of the Biology of Inducible Pluripotent Stem Cells Will Evolve: Predictions on Methods of Stem Cell Induction and the Impact on Cell-Based Therapy, James Thomson, University of Wisconsin, Madison, WISOURCE Cellular Dynamics International